Mark Gordon is a partner and 28-year veteran of Wachtell, Lipton, Rosen & Katz’s Corporate Department, where he focuses on advising public companies and major leveraged buyout firms in domestic and cross-border mergers and acquisitions, shareholder activism, takeover defense, restructurings, corporate governance and securities law matters. Mark is recognized as one of the 500 leading dealmakers in America by Lawdragon and was selected by The American Lawyer as a Dealmaker of the Year for 2016.

Mr. Gordon is also the Robert B. and Candice J. Haas Lecturer in Corporate Finance Law at Harvard Law School, where he has taught a winter-term advanced Mergers & Acquisitions course annually since 2009.

Mr. Gordon joined Wachtell Lipton in 1994 and was elected partner in 2001.  He received his B.A. magna cum laude from Yale University, and his J.D. magna cum laude from Harvard University.  While at Harvard, he was executive editor of the Harvard Civil Rights-Civil Liberties Law Review and was a member of the winning team in the Ames Moot Court Competition.

In addition, Mr. Gordon serves as:

• a member of the executive committee of the board of the USC Shoah Foundation Institute for Visual History and Education,
• a permanent advisor to the Next Generation Leadership group of G100 (an organization focused on the development of future CEOs), and
• a trustee of the Yale Daily News Foundation.

His recent M&A representations include:

• LKQ Corp. in its $2.1 billion acquisition of Uni-Select
• Whirlpool Corporation in its $3 billion acquisition of the InSinkErator business of Emerson Electric
• Cornerstone Building Brands in its $5.8 billion all-cash acquisition by affiliates of Clayton, Dubilier & Rice, its 49% stockholder
• Jazz Pharmaceuticals in its $7.2 billion acquisition of GW Pharmaceuticals
• Alexion Pharmaceuticals in its $39 billion sale to AstraZeneca
• Analog Devices in its $21 billion all-stock acquisition of Maxim Integrated Products
• Craft Brew Alliance in its $320 million sale to Anheuser-Busch InBev
• Auris Health in its $5.75 billion sale to Johnson & Johnson
• Entegris in its merger of equals with Versum Materials with a combined enterprise value of $9 billion (since terminated)
• Energen in its $9.2 billion all-stock merger with Diamondback Energy
• Resolute Energy in its $1.6 billion sale to Cimarex Energy
• NCI Building Systems in its $2.6 billion stock-for-stock merger with Ply Gem
• Eli Lilly and Company in its $1.6 billion acquisition of ARMO BioSciences
• Chicago Bridge & Iron in its $6 billion merger of equals with McDermott International
• Bill Barrett in its $649 million combination with Fifth Creek Energy
• CardConnect in its $750 million acquisition by First Data
• Medivation in its $14 billion sale to Pfizer
• Analog Devices in its $14.8 billion acquisition of Linear Technology
• Valspar in its $11.3 billion sale to Sherwin-Williams
• Airgas $13.4 billion acquisition by Air Liquide S.A.
• Alexion in its $8.4 billion acquisition of Synageva Biopharma
• PetSmart in its $8.3 billion sale to a buying group led by BC Partners
• Steris Corp. in its $1.9 billion acquisition of Synergy Health plc
• Forest Oil in its $1.0 billion merger with Sabine Oil & Gas